NLRP3 and gout: Recently, HMG-CoA reductase inhibitors including atorvastatin, simvastatin, and mevastatin inhibited the activation of the MSU-induced NLRP3 inflammasome by the up-regulation of the peroxisome proliferator-activated receptor-γ (PPAR-γ), resulting in anti-inflammatory therapeutic action in gout [23].